natgillin/translations-raw huggingface dataset:
A method for treatment of a condition selected from the group consisting of a compromised lactation condition, labour induction impairment, a uterine atony condition, inflammation, pain, male and female sexual dysfunction, irritable bowel syndrome (IBS), constipation, gastrointestinal obstruction, autism, stress, anxiety, depression, anxiety disorder, surgical blood loss, post-partum haemorrhage, wound healing, infection, mastitis, placenta delivery impairment, and osteoporosis, wherein said method comprises administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 1 . 
Spoj prema bilo kojem od zahtjeva 1-3, naznačen time da se upotrebljava u liječenju jednog ili više narušenih uvjeta dojenja, oštećenja nakon induciranog poroda, uvjeta atonije maternice, pretjeranog krvarenja, upale, boli, abdominalne boli, boli leđa, muške 1 ženske seksualne disfunkcije, sindroma iritabilnog crijeva (1B5), zatvora, gastrointenstinalnog začepljenja, autizma, stresa, anksioznosti, depresije, poremećaja anksioznosti, gubitka krvi uslijed kirurških zahvata, postporođajnog krvarenja, zacjeljivanja rana, infekcije, mastitisa, oštećenja porođajne posteljice i osteoporoze.
Ar2 is tetrazolyl, triazolyl, imidazolyl, pyrazolyl, pyrrolyl, or dioxothiazinyl, and is substituted with 0-2 substituents selected from the group consisting of amino, oxo, halo, cyano, and C1-6alkyl; and 
Ar? je tetrazolil, triazolil, imidazolil, pirazolil, pirolil ili dioksotiazinil, i supstituiran je sa 0-2 supstituenta izabrana iz grupe koju čine amino, okso, halo, cijano i C,.galkil; i
represents hydrogen, or 
R* predstavlja vodik, ili
Example 9 Overall Procedure 
Primjer 9 - Ukupni postupak
Composition according to any of the claims from 1 to 6, characterized in that glidant is chosen from a group comprising: stearic acid, magnesium stearate, glyceryl behenate, sodium stearyl fumarate. 
Sastav prema bilo kojem od zahtjeva 1 do 5, naznačen time da je sredstvo za podmazivanje odabrano iz grupe koja obuhvaća: stearinsku kiselinu, magnezijev stearat, gliceril behenat, natrijev stearil fumarat.
A packaging according to any of claims 1-3, wherein the hinge allows the sides to be rotated relative to each other within an angle of 180° or more, such as 190° or 200° or 210° or 220° or 230° or 240° or more than 240°. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time, što pant omogućava da se strane zakreću jedna u odnosu na drugu unutar kuta od 180" ili više, kao što je 190" ili 200% ili 210? ili 220% ili 230% ili 240% ili više od 240".
reacting the compound of the above formula IIIb with an organoborane compound of formula 
N) reakciju smjese gore navedene formule IITb s organoboranskim spojem formule, iizus pa
The method of claim 1, wherein the metal carbonyl compound comprises an anionic metal carbonyl, optionally: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što metalni karbonilni spoj sadrži anionski metalni karbonil, izborno:
This invention relates to the method of manufacturing of 7-ethyl-10-hydroxycamptothecin of formula I which is used for manufacturing of cytostatically active irinotecan hydrochloride trihydrate, effective particularly in treatment of lung and rectum cancer. 
Područje izuma Ovaj izum odnosi se na postupak dobivanja 7-etil-10-hidroksikamptotecina formule I kojeg se upotrebljava u dobivanju citostatski aktivnog irinotekan-hidroklorid trihidrata, osobito djelotvornog u liječenju raka pluća i rektuma.
The device of any one of claims 1 to 9, further comprising a support for maintaining the height of the channel, the support being disposed within the channel and extending between the separation element and the surface of the void. 
Uređaj prema jednom od patentnih zahtjeva 1 do 9, da nadalje sadrži nosač za zadržavanje visine kanala, nosač je smješten unutar kanala 1 pruža se između elementa odvajanja i površine praznine.
The process according to claim 1, wherein the ground calcium carbonate particles and/or the precipitated calcium carbonate particles have a specific surface area of from 1 m2/g to 11 m2/g, measured using nitrogen and the BET method. The process according to claim 1, wherein the hydrophobising agent is selected from the group consisting of pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, lauric acid, tridecanoic acid, myristic acid, pentadecanoic acid, palmitic acid, heptadecanoic acid, stearic acid, nonadecanoic acid, arachidic acid, heneicosylic acid, behenic acid, tricosylic acid, lignoceric acid, and any mixture thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se hidrofobirajuće sredstvo bira iz skupine koju čine pentanska kiselina, heksanska kiselina, heptanska kiselina, oktanska kiselina, nonanska kiselina, dekanska kiselina, undekanska kiselina, laurinska kiselina, tridekanska kiselina, miristinska kiselina, pentadekanska kiselina, palmitinska kiselina, heptadekanska kiselina, stearinska kiselina, nonadekanska kiselina, arahidinska kiselina, heneikozilinska kiselina, behenska kiselina, trikozilinska kiselina, lignocerinska kiselina i njihove smjese, poželjno se hidrofobirajuće sredstvo bira iz skupine koju čine oktanska kiselina, dekanska kiselina, laurinska kiselina, miristinska kiselina, palmitinska kiselina, stearinska kiselina, arahidska kiselina i njihove smjese i najpoželjnije se hidrofobirajuće sredstvo bira iz skupine koju čine miristinska kiselina, palmitinska kiselina, stearinska kiselina i njihove smjese.
An anti-TNF-alpha single domain antibody (sdAb), wherein the anti-TNF-alpha sdAb comprises the amino acid sequence as set forth in SEQ ID NO:45. 
Izolirani polipeptid, naznačen time što izolirani polipeptid sadrži anti-STAT3 antitijelo s jednom domenom (sdAb) koje sadrži aminokiselinsku sekvencu kao što je navedena u SEQ ID NO:3.
In the case of the compositions containing interferon beta-1 influenzalike symptoms, skin reactions and local pain - as consequences of the subcutaneous administration - may occur, and disorders of the blood picture, increased level of the liver enzymes, as well as personality disorders may also appear (Eber et al., Lancet 352, 1498-1504, (1998); Jacobs et al., Mult. 
U slučaju sastava koji sadrži interferon beta-1 mogu se javiti simptomi slični gripi, reakcije kože i lokalna bol-kao posljedica subkutane primjene, kao i poremećaji u krvnoj slici, povećana koncentracija jetrenih enzima, kao i poremećaji ličnosti (Eber et al., Lancet 352, 1498-1504, (1998); Jacobs et al., Mult.
The locking panel socket as claimed in claim 10, in which the linking portion is not of a unitary construction, but is composed of separate pieces. 
Panel utičnica (1) sa zaključavanjem prema bilo kojem od prethodnih zahtjeva, naznačena time da dio za spajanje nije unitarne konstrukcije, već se sastoji od odvojenih dijelova.
Cy2 is selected from a substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; 
Cy2 se odabire od supstituirane ili nesupstituirane heterocikličke skupine, supstituiranog ili nesupstituiranog arila i supstituiranog ili nesupstituiranog heteroarila;
for compounds of formula I wherein A represents S, and Q is a bond, -O- or -S-, reaction of a compound of formula VII, wherein W and D are as defined in Claim 1, with a compound of formula VIII, wherein A1 to A5, n, Rx and Ry are as defined in Claim 1, L5 is a suitable leaving group and Q is a bond, -O- or -S-; 
za spojeve s formulom I pri čemu A predstavlja S, i Q je veza, -O- ili -S-, reakcijom spoja s formulom VII, [image] pri čemu W i D su kako je definirano u zahtjevu 1, sa spojem s formulom VIII, [image] pri čemu A1 do A5, n, Rx i Ry su kako je definirano u zahtjevu 1, L5 je prikladna izlazna skupina i Q je veza, -O- ili -S-;
Emission of indicating pulses of the receiver. 
Broj objave europskog patenta:
A make and break threaded pipe connection capable of being screwed together and subsequently unscrewed, the threaded pipe connection comprising: 
„Make and break“ cijevni priključak s navojem koji se može navinuti i naknadno odvinuti, cijevni priključak s navojem obuhvaćajući:
The matrix metalloproteinase inhibitor for use according to claim 6, wherein the second agent is selected from anti-hepatitis C virus interferon, ribavirin or a combination thereof. 
Inhibitor matričnih metaloproteinaza namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što drugo sredstvo se bira između interferona protiv virusa hepatitisa C, ribavirina ili njihove kombinacije.
The invention provides an isolated IL-23p19 antibody, comprising: 
Izolirano IL-23p19 antitijelo, koje je antitijelo koje se veže za p19 podjedinicu IL-23, obuhvaćajući:
A method according to claim 10 characterised in that the achiral acid is selected from the group consisting of organic acids such as formic acid, acetic acid, trifluoroacetic acid and methanesulfonic acid, more particularly acetic acid. 
Postupak prema zahtjevu 7, naznačen time što je ahiralna kiselina izabrana iz grupe koja se sastoji od organskih kiselina.
The antibody or antigen binding fragment for use as claimed in claim 1 or 2, wherein the antibody, or antigen binding fragment comprises a heavy chain variable region having at least 80%, 90%, 95%, 97%, 98% or 99% sequence identity to an amino acid sequence of SEQ ID NO: 7; and a light chain variable region having at least 80%, 90%, 95%, 97%, 98% or 99% sequence identity to an amino acid sequence of SEQ ID NO: 8. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema zahtjevu 1, naznačen/o time, da obuhvaća varijabilno područje jakog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% 1li 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:7; 1 varijabilno područje slabog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:8.
The said body of permanent-magnetic material is preferably a polymer-bonded composite as already described before. 
Navedeno tijelo od permanentno magnetskog materijala poželjno je izrađeno od kompozita vezanog polimerom kako je već prije opisano.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
In particular, it is proposed to add different reagents into a well and to influence strata by elastic vibrations of different frequency, shock waves, magnetic and electric fields or combinations thereof. 
Posebno, predlaže se dodavanje različitih reagenasa u izvor i djelovanje na naslage elastičnim vibracijama različite frekvencije, udarnim valovima, magnetskim i električnim poljima ili njihovim kombinacijama.
A combination for use according to claim 9, wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija sukladno patentnom zahtjevu 9, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV 1 (b) B2 agonista.
reduces the fibrosis. 
smanjuje sadržaj kolagena.
means for receiving (1102) a multimedia broadcast multicast service MBMS service (940) from a first cell (912) in a first multicast broadcast single frequency network MBSFN area (910) while in a radio resource control RRC idle mode; 
sredstvo (1102) za primitak MBMS servisa (940) od prve stanice (912) u prvom MBSFN području (910) dok se nalazi u RRC neaktivnom režimu;
The method of claim 5, wherein the matrix comprises one or more of transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), insulin-like growth factor 1, bovine fibroblast growth factor (bFGF), and/or platelet-derived growth factor (PDGF). 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što matriks sadrži jedan ili više od transformirajućeg čimbenika rasta B (TGFB), čimbenika rasta epiderme (EGF), inzulinu sličnog čimbenika rasta 1, goveđeg čimbenika rasta fibroblasta (bFGF), i/ili čimbenika rasta iz trombocita (PDGF).
neutralizing agent in sufficient quantity to position the formulation's pH between 2 and 6, a pharmacologically active agent, 
- najmanje jedno sredstvo za neutraliziranje, u količini dovoljnoj da pH formulacije bude između 2 i 6,
adding a base to said first leach solution, after said step of separating insoluble residues, causing precipitation of phosphate compounds comprising at least one of iron and aluminium from said first leach solution; 
dodavanje (220) baze u spomenutu prvu otopinu za ispiranje, nakon spomenutog koraka razdvajanja (210) netopivih ostataka, čime se izaziva taloženje fosfatnih spojeva koji sadrže barem jedan od željeza ili aluminija iz spomenute prve otopine za ispiranje;
Preferable heteroatoms are oxygen, nitrogen and sulfur. 
Poželjni heteroatomi su kisik, dušik i sumpor.
In order to ascertain that the FAME was not lost through evaporation during the curing process, the weight loss was monitored during heating using Thermal Gravimetric Analysis (TGA). 
Da se utvrdi kako se FAME nije izgubio isparavanjem tijekom procesa skručivanja, tijekom grijanja je praćen gubitak mase pomoću toplinske gravimetrijske analize (TGA).
applying the solution comprising the antibody of the IgG class to the equilibrated chromatography material and thereby loading the chromatography material, producing the antibody of the IgG class in monomeric form by applying a solution to the chromatographic material comprising poly (ethylene glycol) and sorbitol and thereby desorbing/eluting the antibody of the IgG class in monomeric form from the chromatographic material, 
- proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IeG- razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % i sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
The method of claim 1 wherein the steam turbine generator comprises two or more sections and the first portion of the output is obtained from a first section of the steam turbine generator and the reheated steam is delivered to a second section of the steam turbine generator. 
Postupak sukladno zahtjevu 2, pri čemu parna turbina-generator sadrži dvije ili više sekcija i prvi dio izlaza se dobiva iz prve sekcije parne turbine-generatora, dok se prva ponovo zagrijana para dovodi do druge sekcija parne turbine-generatora.
The composition of Claim 7, wherein the compound is selected from: Compound 131; Compound 122; Compound 114; Compound 106; Compound 104; Compound 120; and Compound 123 or a pharmaceutically acceptable salt of any of the foregoing. 
Kompozicija prema zahtjevu 7, gdje se spoj bira od spoja 131, spoja 122, spoja 114, spoja 106, spoja 104, spoja 120 i spoja 123 ili farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih spojeva.
The polymer composition according to claim 27 or 28, wherein the polymer composition is a masterbatch, wherein the masterbatch comprises the surface treated filler material product in an amount of from 50 to 85 wt.-%, preferably from 60 to 85 wt.-% and more preferably from 70 to 80 wt.-%, based on the total weight of the masterbatch. 
Polimerni pripravak prema zahtjevu 27 ili 28, naznačen time da polimerni pripravak je glavna šarža, pri čemu glavna šarža sadrži proizvod površinski obrađenog materijala punila u količini od 50 do 85 tež.-%, poželjno od 60 do 85 tež.-% i poželjnije od 70 do 80 tež.-%, u odnosu na ukupnu težinu glavne šarže.
A compound of claim 1, which is selected from the following: TABLE 4 R2 
Spoj formule I za uporabu kao što je definirano u patentnom zahtjevu 1 koji je:
Finally, the invention also comprises the veneer itself which can be obtained from the process according to the invention or which is obtained by cutting along a defined section plane from the beam-like block of wood. 
Na kraju, ovaj izum također obuhvaća sam furnir koji se može dobiti iz postupka koji je u skladu s ovim izumom ili koji se dobiva rezanjem duž određene ravne sekcije bloka od drva koji ima oblik grede.
The compound or a salt thereof, or a solvate of these according to any one of claims 1 to 17, wherein R7 is a hydrogen atom, hydroxyl group, methyl group, ethyl group, methoxy group, ethoxy group or fluorine atom. 
Spoj ili njegova sol ili solvat u skladu s bilo kojim patentnim zahtjevom 1 do 17, naznačen time, daje R atom vodika, hidroksilna skupina, metilna skupina, etilna skupina, metoksi skupina, etoksi skupina ili atom fluora.
The print medium of any of the preceding claims, wherein the absorptive layer comprises a pigment, which, when in the form of a compacted bed, has an absorption rate from 1×10-5 ms-0.5 to 1×10-3 ms-0.5 and/or a volume uptake from 35 to 95 % by volume relative to the total volume of the pigment. 
Tiskovna podloga prema bilo kojem od prethodnih zahtjeva, naznačena time da apsorpcijski sloj sadrži pigment, koji, kada je u kompaktnom obliku, ima stupanj upijanja od 1x10? ms"? do 1x10% ms"> i/ili unos volumena od 35 do 95 % volumena u odnosu na ukupni volumen pigmenta.
A dispenser as claimed in claim 35, 36 or 37, further comprising a tolerance adjustment mechanism. 
Dispenzer kao što je navedeno u zahtjevu 32, 33 ili 34, dalje sadržeći mehanizam za prilagodbu tolerancije.
The new.method changes the European - style veneer process such that for all surface patterns that are "plank match", e.g. lumber-look-alikes, the subsequent manufacturing step (the clipping/trimming of the veneer and the labor intensive assembling/splicing process) becomes obsolete. 
Novi postupak mijenja europski način postupka za izradu furnira tako, da svi površinski uzorci koji su "složeni kao ploča", na primjer, izgledaju kao greda, sljedeća proizvodna faza (podrezivanje/podešavanje furnira) i intenzivan rad na postupku slaganja/spajanja) postaju vrlo precizni.
In a potential embodiment, the air scenting device according to the present disclosure may exhibit the alternative or additional feature that the outflow opening is oriented downward, out of the housing relative to the chamber. 
Sklop u skladu sa patentnim zahtjevom 1, gdje navedeni otvor za otpuštanje je orijentiran prema dole, izvan navedenog kućišta u odnosu na navedenu komoru.
The pharmaceutical composition according to any one of the preceding claims, wherein the mRNA encodes two or more distinct proteins. 
Nosač transfera prema bilo kom od zahtjeva 2 do 8, naznačen time što nosač transfera nadalje sadrži jedno ili više terapeutskih ili dijagnostičkih sredstava.
The compound or salt for use according to claim 1, wherein said cancer is selected from cancer of the colon, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma. 
Spoj, sol ili sastav prema patentnom zahtjevu 32, naznačen time da je spomenuti rak odabran od raka kolona, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, raka vrata materice, raka testisa, raka bubrega, raka glave i vrata, limfoma, leukemije i melanoma.
In all of the various aspects of the invention, the carbon marked C* may be asymmetric (when R4 is not H) and in this event it will be appreciated that compounds of the formula I may exist in racemic form, or may be separated into their (+) or (−) enantiomers by conventional methods. 
U svim od različitih aspekata izuma, ugljik označen C* može biti asimetričan (kada R* nije H) i u ovom slučaju uvidjet će se da spojevi formule I mogu postojati u racemičnom obliku, ili mogu biti razdvojeni na svoje (+) ili (-) enantiomere konvencionalnim metodama.
A system for preparing a predetermined quantity of beverage suitable for consumption using an extractable product, comprising a capsule (2) comprising: 
Kapsula (2) prema zahtjevu 1, naznačena time, da su grebeni (28.i) raspoređeni na izbočenom okviru (20).
Composition as in any claim hereinbefore, characterized in that the sucrose-ester selected is one or more from among saccharose monopalmitate, saccharose monostearate, saccharose dipalmatate, saccharose distearate, saccharose alchilate or mixtures of two or more of these. 
Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time da je odabrani sukroza-ester jedan ili više od saharoza monopalmitata, saharoza monostearata, saharoza dipalmitata, saharoza distearata, saharoza alhilata ili smjese dva ili više od navedenih.
In one embodiment, the antibody of the present invention is an IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibody. 
Protutijelo sukladno patentnom zahtjevu 1, karakterizirano time da je u punoj duljini IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, ili IgM protutijelo.
The solid form of claim 1, wherein the XRPD pattern further comprises peaks at approximately 7.10, 16.35, and 28.36 degrees 2θ. 
Čvrsti oblik prema zahtjevu 1, naznačen time što XRPD uzorak nadalje sadrži vrhove na približno 17.65, 22.47 i 26.77 stupnjeva 2Ɵ.
a single molecule DNA-targeting RNA that comprises, in 5′ to 3′ order: a targeter-RNA that hybridizes with a target sequence of the target DNA; and 
RNK jednostruke molekule koja cilja na DNK, te koja obuhvaća sljedeće: segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK; i
In some embodiments the first and/or second outer part serves as the antenna and thus the ability of the metal part to transmit fields/signals may be utilised. 
U nekim ostvarenjima prvi i drugi vanjski dio služe kao antena i na taj način se može iskoristiti sposobnost metalnog dijela za odašiljanje polja/signala.
The process of claim 1, wherein the residuum hydrocarbon (10) is a vacuum residuum feedstock derived from one or more of Arab Heavy, Arab Light, Banoco Arab Medium, Kuwait Export, Basrah Light, Rubble, Bahrain, Oman, Upper Zakam, REBCO, Kumkol, Azeri Light, Siberian Light, Siberian Heavy, and Tengiz petroleum crude oils. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je ugljikovodični ostatak (10) ostatak sirovine 12 vakuumskog postupka koji potječe od jedne ili više vrsta sirove nafte: Arab Heavy, Arab Light, Banoco Arab Medium, Kuwait Export, Basrah Light, Rubble, Bahrain, Oman, Upper Zakam, REBCO, Kumkol, Azeri Light, Siberian Light, Siberian Heavy, i Tengiz.
Preferably, compound of formula (XXIV) is prepared in three steps, the three steps are a step (Q1), a step (Q2) and a step (Q3); 
Postupak prema zahtjevu 6, naznačen time da spoj formule (XXIV) bude spravljen u tri koraka, pri čemu se radi o tri koraka, korak (Q1), korak (Q2) i korak (Q3);
The process of paragraph 58, wherein the step of converting Compound 10 to Compound 6 comprises reacting Compound 10 with Wittig reagent. 
Postupak u skladu s patentnim zahtjevom 48, naznačen time što korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s Wittigovim reagensom, 52.